Advertisement

Charles River Laboratories International, Inc. CRL

Set alert

Price alert · CRL

All alert types
359.41 USD -16.69 -4.44%

At close · Oct 30

365.29 +5.88 +1.64%

After hours · Oct 30, 7:07 PM ET

Bid
359.26 × 300
Ask
359.75 × 200
351.98 Day range 374.40
149.93 52-week range 376.10
YTD
+80.17%
1 year
+100.66%
Open
372.99
Prev close
376.10
Mkt cap
17.16B
Vol
1.50M
Avg vol
1.02M
EPS
-4.80
P/E
0.00
Div yield
0.00%
More statistics
Low
351.98
High
374.40
Forward P/E
28.20
Beta
1.40
Short ratio
2.77
Inst. own
122.19%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
300.55
200-d avg
221.07
1y target
318.87

2Y chart

Chart tools
Interval

Events in this range
  • Aug 6, 2025Earnings: 3.12; estimate 2.5; surprise 24.8%
  • Nov 5, 2025Earnings: 2.43; estimate 2.32; surprise 4.74%
  • Feb 18, 2026Earnings: 2.39; estimate 2.33; surprise 2.58%
  • May 7, 2026Earnings: 2.06; estimate 1.96; surprise 5.1%
  • Aug 5, 2026Earnings: 3.02; estimate 2.74; surprise 10.22%
  • Sep 25, 2026Rating: RBC Capital · Outperform → Outperform
  • Sep 25, 2026Rating: Evercore ISI Group · Outperform → Outperform
  • Sep 25, 2026Rating: TD Cowen · Buy → Buy
  • Sep 25, 2026Rating: Deutsche Bank · Buy → Buy
  • Sep 28, 2026Rating: Jefferies · Buy → Buy
  • Oct 13, 2026Rating: Morgan Stanley · Overweight → Overweight
Signals (106)
NameDateAgo
RSI: OverboughtOct 21, 20261 week ago
MACD: Buy SignalOct 20, 20261 week ago
MACD: Sell SignalOct 16, 20262 weeks ago
MACD: Buy SignalSep 25, 20261 month ago
MACD: Sell SignalAug 27, 20262 months ago
MACD: Buy SignalAug 5, 20262 months ago
RSI: OverboughtAug 5, 20262 months ago
MACD: Sell SignalJul 15, 20263 months ago
RSI: OverboughtJul 9, 20263 months ago
RSI: OverboughtJun 25, 20264 months ago
MACD: Buy SignalJun 24, 20264 months ago
MACD: Sell SignalJun 22, 20264 months ago
SMA: BullishJun 3, 20265 months ago
SMA: BearishJun 2, 20265 months ago
SMA: BullishMay 28, 20265 months ago
SMA: BullishMay 28, 20265 months ago
MACD: Buy SignalMay 28, 20265 months ago
SMA: BearishMay 11, 20265 months ago
SMA: BearishMay 11, 20265 months ago
MACD: Sell SignalMay 11, 20265 months ago
MACD: Buy SignalMay 6, 20265 months ago
SMA: BullishMay 5, 20265 months ago
SMA: BullishMay 4, 20266 months ago
SMA: BearishApr 28, 20266 months ago
SMA: BullishApr 24, 20266 months ago
MACD: Sell SignalApr 24, 20266 months ago
SMA: BearishApr 23, 20266 months ago
SMA: BearishApr 23, 20266 months ago
SMA: BullishApr 8, 20266 months ago
SMA: BullishApr 8, 20266 months ago
SMA: BearishApr 6, 20266 months ago
SMA: BullishApr 1, 20267 months ago
MACD: Buy SignalMar 24, 20267 months ago
MACD: Sell SignalMar 12, 20267 months ago
SMA: BearishMar 10, 20267 months ago
SMA: BullishFeb 26, 20268 months ago
MACD: Buy SignalFeb 26, 20268 months ago
SMA: BearishFeb 11, 20268 months ago
RSI: OversoldFeb 11, 20268 months ago
RSI: OversoldFeb 5, 20268 months ago
SMA: BearishFeb 4, 20268 months ago
MACD: Sell SignalJan 23, 20269 months ago
MACD: Buy SignalJan 21, 20269 months ago
RSI: OverboughtJan 21, 20269 months ago
MACD: Sell SignalJan 20, 20269 months ago
RSI: OverboughtJan 15, 20269 months ago
MACD: Buy SignalJan 5, 20269 months ago
RSI: OverboughtJan 5, 20269 months ago
MACD: Sell SignalDec 31, 202510 months ago
RSI: OverboughtDec 22, 202510 months ago
RSI: OverboughtDec 15, 202510 months ago
RSI: OverboughtDec 10, 202510 months ago
MACD: Buy SignalNov 25, 202511 months ago
SMA: BullishNov 24, 202511 months ago
SMA: BearishNov 14, 202511 months ago
MACD: Sell SignalOct 30, 20251 year ago
RSI: OverboughtOct 23, 20251 year ago
RSI: OverboughtOct 21, 20251 year ago
SMA: BullishOct 1, 20251 year ago
MACD: Buy SignalOct 1, 20251 year ago
SMA: BullishSep 30, 20251 year ago
SMA: BearishSep 12, 20251 year ago
SMA: BullishSep 11, 20251 year ago
SMA: BearishSep 9, 20251 year ago
SMA: BearishSep 9, 20251 year ago
MACD: Sell SignalSep 9, 20251 year ago
MACD: Buy SignalAug 25, 20251 year ago
SMA: BullishAug 22, 20251 year ago
SMA: BullishAug 22, 20251 year ago
SMA: BearishAug 21, 20251 year ago
SMA: BullishAug 15, 20251 year ago
SMA: BearishAug 6, 20251 year ago
MACD: Sell SignalAug 4, 20251 year ago
RSI: OverboughtJul 24, 20251 year ago
MACD: Buy SignalJul 23, 20251 year ago
MACD: Sell SignalJul 15, 20251 year ago
RSI: OverboughtJul 10, 20251 year ago
MACD: Buy SignalJul 1, 20251 year ago
MACD: Sell SignalJun 18, 20251 year ago
MACD: Buy SignalJun 4, 20251 year ago
MACD: Sell SignalMay 30, 20251 year ago
SMA: BullishMay 23, 20251 year ago
SMA: BearishMay 21, 20251 year ago
SMA: BullishMay 16, 20251 year ago
SMA: BearishMay 14, 20251 year ago
SMA: BullishMay 12, 20251 year ago
MACD: Buy SignalApr 24, 20251 year ago
RSI: OversoldApr 21, 20251 year ago
RSI: OversoldApr 10, 20251 year ago
RSI: OversoldApr 3, 20251 year ago
SMA: BearishMar 25, 20251 year ago
SMA: BullishMar 21, 20251 year ago
MACD: Sell SignalMar 21, 20251 year ago
SMA: BearishMar 20, 20251 year ago
SMA: BullishMar 14, 20251 year ago
SMA: BearishMar 13, 20251 year ago
SMA: BullishMar 12, 20251 year ago
SMA: BearishMar 11, 20251 year ago
SMA: BullishMar 7, 20251 year ago
MACD: Buy SignalFeb 19, 20251 year ago
RSI: OversoldFeb 13, 20251 year ago
MACD: Sell SignalFeb 12, 20251 year ago
MACD: Buy SignalFeb 5, 20251 year ago
RSI: OversoldJan 17, 20251 year ago
MACD: Sell SignalJan 15, 20251 year ago
MACD: Buy SignalJan 6, 20251 year ago

Key statistics

Market cap
17.16B
Enterprise value
20.85B
Trailing P/E
0.00
Forward P/E
28.20
PEG ratio
0.12
Price / sales
4.29
Price / book
6.04
EPS (TTM)
-4.80
Beta
1.40
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-5.96%
Revenue (TTM)
4.00B
Revenue growth
-2.70%
Free cash flow
468.86M
Total cash
192.02M
Total debt
3.03B
Return on equity
-7.52%
Shares outstanding
47.74M
Short % of float
6.86%
50-day average
300.55
200-day average
221.07

Analyst view

Consensus: buy

Buy
Price target (mean) 318.87 -11.3% downside
Target (low)
145.00
Target (mean)
318.87
Target (high)
390.00
Ratings (0m) 17 14 buy · 2 hold · 1 sell
  • Strong buy3
  • Buy11
  • Hold2
  • Sell1
  • Strong sell0

Next earnings

Nov 4, 2026

Expected Nov 4, 2026. Consensus EPS estimate 2.97.

Earnings history

Financials — quick view

All financials
CRL Revenue — quarterly 1.00B
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CRL Net income — quarterly -1.48M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
CRL EPS — quarterly -0.03
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

CRL recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 4, 2026Sep 27, 20262.97———
Aug 5, 2026Jun 27, 20262.743.02+0.28+10.22%
May 7, 2026Mar 28, 20261.962.06+0.10+5.10%
Feb 18, 2026Dec 27, 20252.332.39+0.06+2.58%
Nov 5, 2025Sep 27, 20252.322.43+0.11+4.74%
Aug 6, 2025Jun 28, 20252.503.12+0.62+24.80%

Upgrades / downgrades

CRL analyst upgrades and downgrades
DateFirmActionFromTo
Oct 13, 2026Morgan StanleymainOverweightOverweight
Sep 28, 2026JefferiesmainBuyBuy
Sep 25, 2026Deutsche BankmainBuyBuy
Sep 25, 2026TD CowenmainBuyBuy
Sep 25, 2026Evercore ISI GroupmainOutperformOutperform
Sep 25, 2026RBC CapitalmainOutperformOutperform

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services; and engages in development and production of cell therapies. The Discovery and Safety Assessment segment offers in vitro and in vivo discovery services for the discovery, development, and safety testing of novel drugs, molecule compounds, oligonucleotides, and biotherapeutics, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services; and vivarium space services. The Manufacturing Solutions segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products; offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and contract development and manufacturing products and services. The company has collaborations with Parker Institute for Cancer Immunotherapy and Children's Hospital Los Angeles across its contract development and manufacturing organization; and Medigen Vaccine Biologics Corp for developing next-generation multivalent enterovirus vaccine, enhance global regulatory readiness, and support IND-enabling non-clinical studies. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
criver.com

News

Your note

Sign in to keep a note on CRL — it syncs with the Stock Master app.

Insider holders

CRL insider holders
InsiderRelationLatest transactionDateShares held
BARBO WILLIAM DOfficerStock GiftNov 6, 20240
COLEMAN GLENN GChief Financial OfficerStock Award(Grant)May 28, 202627,752
CREAMER VICTORIA LOfficerSaleAug 5, 202630,051
FOSTER JAMES CDirectorSaleOct 21, 2026233,410
GIRSHICK BIRGITChief Executive OfficerStock GiftAug 18, 202679,288
LAPLUME JOSEPH WOfficerStock GiftAug 9, 202631,041

Institution ownership

CRL institution ownership
Holder% heldSharesValueReported
FMR, LLC8.88%4,239,7521.52BJun 29, 2026
Blackrock Inc.7.96%3,798,5601.37BJun 29, 2026
Vanguard Capital Management LLC6.60%3,149,2881.13BJun 29, 2026
Invesco Ltd.6.25%2,984,7851.07BJun 29, 2026
Harris Associates L.P.4.69%2,241,144805.58MJun 29, 2026
Vanguard Portfolio Management LLC4.63%2,210,979794.74MJun 29, 2026

Fund ownership

CRL fund ownership
Holder% heldSharesValueReported
Fidelity Contrafund3.82%1,825,159656.05MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.21%1,530,171550.02MJun 29, 2026
HARRIS ASSOCIATES INVESTMENT TRUST-Oakmark Select Fund3.14%1,498,000538.46MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard 500 Index Fund2.61%1,247,732448.50MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.31%1,104,850397.14MJun 29, 2026
ALLSPRING FUNDS TRUST-Allspring Special Mid Cap Value Fund1.64%784,906282.13MAug 30, 2026
Advertisement